

Maternal immunization: understanding safety and efficacy and making a strong recommendation

Lakshmi Sukumaran, MD, MPH

Medical Officer, Immunization Safety Office

Ashley Brooks, MPH

Health Communication Specialist

National Center for Immunization and Respiratory Diseases

ACOG/ACNM Maternal Immunization Webinar

March 1, 2018



ACCME Accreditation

The American College of Obstetricians and Gynecologists is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA PRA Category 1 Credit(s)TM

The American College of Obstetricians and Gynecologists designates this **enduring material** for a maximum of 1 *AMA PRA Category 1 CreditTM*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

College Cognate Credit(s)

The American College of Obstetricians and Gynecologists designates this **enduring material** for a maximum of 1 Category 1 College Cognate Credit. The College has a reciprocity agreement with the AMA that allows *AMA PRA Category 1 CreditsTM* to be equivalent to College Cognate Credits.

Disclosure of Faculty and Industry Relationships

In accordance with the College policy, all faculty and planning committee members have signed a conflict of interest statement in which they have disclosed any financial interests or other relationships with industry relative to topics they will discuss at this program. At the beginning of the program, faculty members are expected to disclose any such information to participants. Such disclosure allows you to evaluate better the objectivity of the information presented in lectures. Please report on your evaluation form any undisclosed conflict of interest you perceive. Thank you!

This webinar was made possible by cooperative agreement number 6 5 NU38OT000161-05-00 from the Centers for Disease Control and Prevention (CDC) and the Association of State and Territorial Health Officials (ASTHO). Its contents are solely the responsibility of ACOG and do not necessarily represent the official views of CDC or ASTHO.

Our recommended software and hardware configuration is the following:

Windows



Processor: 850MHz or faster processor (or above)
Operating System: Windows XP/2000/98
Memory: 512MB of RAM (or above)
Screen Resolution: 1024 x 768 (or above)
Microsoft Internet Explorer 5.5 (or higher)
or Mozilla Firefox 1.5
Adobe Flash Player 8 (or higher)
Adobe Acrobat 6 (or higher)

Macintosh



Processor: G3 500MHz or faster processor (or above)
Operating System: OS 10.3 (or above)
Memory: 512MB of RAM (or above)
Screen Resolution: 1024 x 768 (or above)
Mozilla Firefox 1.5 or Safari 1.2.2 browser supported for Mac OS X 10.3 or higher
Adobe Flash Player 8 (or higher)
Adobe Acrobat 6 (or higher)

Conflict of Interest Disclosure: Faculty/Planning Committee/Reviewer/Staff

CONFLICT OF INTEREST DISCLOSURE: FACULTY/PLANNING COMMITTEE/REVIEWER/STAFF

Kevin A. Ault, MD – Research: Inovio and NIH; Consultant: ACI Clinical, Moderna Therapeutics, NIH, CDC, and ACOG; Data and Safety Monitoring Board: NIH, CDC and Novartis

Brenna L. Hughes, MD – Royalties from UpToDate for authorship; Scientific Advisory: Merck

Flor Munoz, MD – Author and Editorial Board: UpToDate; DSMB Member: Moderna, NIH, Propel study, Thrasher; Research (CTA through Baylor College of Medicine): Biocryst, Alios, Regeneron, Novavax, CDC respiratory and GI viral surveillance, The National Institutes of Health, BMGF - GAIA project - Vaccine safety; Advisory board: WHO - maternal immunization with influenza/GBS projects

Laura E. Riley, MD – Author: UpToDate; Published Author: Wiley Publishing

Geeta K. Swamy, MD – Research: GSK, Novavax, Regeneron; Independent Data Monitoring Committee: GSK; Chairperson, External Data Monitoring Committee: Pfizer

All other faculty, planning committee members, reviewers and staff have no conflict of interest to disclose relative to the content of the presentation.

Course Faculty

Lakshmi Sukumaran, MD, MPH

Medical Officer, Immunization Safety Office
Centers for Disease Control and Prevention

Ashley Brooks, MPH

Health Communication Specialist
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention

Learning Objectives

- Discuss the scientific evidence supporting maternal flu vaccination safety and monitoring.
- Educate pregnant patients about the importance of an annual flu vaccine.
- Name three components of a strong recommendation.
- Use CDC ACOG, ACNM and messaging and resources to address patient questions and concerns regarding flu immunization.

Disclaimer

- The findings and conclusions in this presentation are those of the author and do not necessarily represent the official position of the CDC

Woman dies of swine flu days after giving birth

A woman who contracted swine flu died just weeks after giving birth to her first child.



56 deaths among US pregnant women



Family: Former Lincoln woman dies of swine flu during childbirth

A former mayor of Boys Town has died, apparently of swine flu. A paid obituary in the Lincoln Journal Star says 20-year-old Caitlin Anne Treat Huber died of swine flu a day after giving birth.

25 per cent of pregnant women vaccinated even though they are four times more at risk of swine flu



The NEW ENGLAND JOURNAL of MEDICINE

Swine flu alert for pregnant women and babies

LISA DONNELLY
 Health correspondent

SWINE FLU causes the illness in the United States to be the most common cause of death in pregnant women and new mothers, but it is not always clear the extent of the risk during the pregnancy. A new report from the Centers for Disease Control and Prevention says that 25 percent of pregnant women are vaccinated against swine flu, even though they are four times more at risk of swine flu than the general population.

The report says that 25 percent of pregnant women are vaccinated against swine flu, even though they are four times more at risk of swine flu than the general population.

The report also says that 25 percent of pregnant women are vaccinated against swine flu, even though they are four times more at risk of swine flu than the general population.



ORIGINAL ARTICLE

Severe 2009 H1N1 Influenza in Pregnant and Postpartum Women in California

Janice K. Louie, M.D., M.P.H., Meileen Acosta, M.P.H.,
 Denise J. Jamieson, M.D., M.P.H., and Margaret A. Honein, Ph.D., M.P.H.,
 for the California Pandemic (H1N1) Working Group*

38-Day-Old Baby Dies After Persisting Cough

By LARA SALAHI · April 28, 2010



Third baby dies from whooping cough in California



Newborn Nearly Dies Contracting Whooping Cough

By MIRIAM KOPPEL

Whooping Cough Back Again With A Vengeance In California



July 23, 2010

Disease burden highest in infants during pertussis epidemic

10 News (10)

By MEL KAZIZ · CBS NEWS · June 29, 2010, 11:49 AM

Whooping Cough Epidemic Rages in California: 5 Babies Dead, 910 Infected

Five babies dead from whooping cough so far this year in biggest outbreak for 20 years



Health + Diet + Fitness | Living Well | Parenting + Family

10 infants dead in California whooping cough outbreak

From Miriam Koppe, CNN

October 29, 2010 10:10 pm EDT



OVERVIEW

- Infections and vaccinations during pregnancy
- CDC vaccine safety monitoring in pregnancy
- Results of inactivated influenza vaccine (IIV) and tetanus, diphtheria, and acellular pertussis (Tdap) safety studies in pregnancy
- Maternal vaccine safety recap



**Vaccination during pregnancy
protects mom and baby**

Infections in pregnant women and neonates


- Maternal influenza
 - Physiologic changes during pregnancy → severe disease¹
 - 5-fold increased risk of death in pregnant women (typically 2nd/3rd trimester)
- Neonatal influenza
 - No infant vaccine until 6 months of age
 - Infants at high risk of hospitalization and death from influenza²
- Neonatal pertussis
 - Primary immunization series complete at 6 months
 - Majority of pertussis deaths occur in infants < 3 months of age³

1. Grohskopf L et al. MMWR (2016).

2. Epperson S et al. MMWR (2014).

3. 2016 provisional pertussis surveillance report: <http://www.cdc.gov/pertussis/downloads/pertuss-surv-report-2014.pdf>

Increased susceptibility to severe influenza infection



Potential impacts of exposures during pregnancy

Pre-implantation
(0-2 weeks)

Embryonic period
(2-9 weeks)

Fetal period
(9 weeks - term)



Injury to a large number of cells → spontaneous abortion

Major defects and altered function of organs

Small for gestational age, intrauterine growth restriction, fetal death, minor malformations, altered function of organs

Recommendations for influenza vaccine during pregnancy


- Advisory Committee on Immunization Practices (ACIP) recommendations for pregnant women
 - 1960: Pregnant women noted to be at risk of severe illness and were recommended to receive influenza vaccine
 - since 1990s: Vaccination during 2nd and 3rd trimesters recommended
 - 2004: Influenza vaccine recommended for all pregnant women during *any* trimester of pregnancy
 - 2017: Any licensed, recommended and age-appropriate trivalent, quadrivalent, or recombinant inactivated influenza vaccine can be administered during pregnancy

Recommendations for Tdap vaccine during pregnancy

- ACIP recommendations in pregnant women¹
 - 2006: Tdap booster to post-partum mothers and family members (cocooning)
 - 2011: Tdap for unvaccinated pregnant women after 20 weeks gestation
 - 2012: Tdap for every pregnant woman at every pregnancy regardless of prior immunization status (optimally between 27-36 weeks gestation)

CDC prioritizes maternal vaccine safety


Vaccine licensure process in the United States



Why post-licensure vaccine safety monitoring?

- Pregnant women often excluded from pre-licensure clinical trials
- Pre-licensure clinical trials may not detect rare events
- Safety standards for vaccines are high

CDC vaccine safety monitoring



CDC vaccine safety monitoring



VAERS

Vaccine
Adverse
Event
Reporting
System



Co-managed by
CDC and FDA

The screenshot shows the VAERS website homepage. At the top, the VAERS logo is followed by the text 'Vaccine Adverse Event Reporting System' and the URL 'www.vaers.hhs.gov'. Below this is a navigation bar with five tabs: 'About VAERS', 'Report an Adverse Event', 'VAERS Data', 'Resources', and 'Submit Follow-Up Information'. The main content area features a large heading 'Have you had a reaction following a vaccination?' with two numbered steps: '1. Contact your healthcare provider' and '2. Report an Adverse Event using the VAERS online form or the new downloadable PDF **Now!**'. A green box contains a 'Important!' notice: 'If you are experiencing a medical emergency, seek immediate assistance from a healthcare provider or call 911. CDC and FDA do not provide individual medical treatment, advice, or diagnosis. If you need individual medical or healthcare advice, consult a qualified healthcare provider.' Below this is a Spanish version of the heading: '¿Ha tenido una reacción después de recibir una vacuna?' with similar numbered steps. To the right of the text is a photograph of a family (a man, a woman, and two children) looking at a laptop. Below the photo is the text 'What is VAERS?'. At the bottom of the page are four small tiles, each with an image and a title: 'REPORT AN ADVERSE EVENT' (with a photo of a doctor and patient), 'SEARCH VAERS DATA' (with a photo of hands on a tablet), 'REVIEW RESOURCES' (with a photo of a woman reading), and 'SUBMIT FOLLOW-UP INFORMATION' (with a photo of a woman at a computer). Each tile has a brief description of the service below the title.

CDC vaccine safety monitoring

VSD

Vaccine
Safety
Datalink



8 participating
healthcare organizations



Identifying pregnancies in the VSD


- VSD uses an validated algorithm¹ to identify pregnancy outcomes and start and end dates from electronic health records
- VSD data can be used to link pregnant women to their children
- VSD annual cohort ~3% of US population²
 - ~125,000 pregnancies per year
 - ~90,000 live births per year
- Additional pregnancy data: Height and weight, education, prior pregnancy history, smoking and alcohol use, plurality, delivery type, Apgars, last menstrual period, estimated due date

1. Naleway AL et al. Vaccine (2013).

2. McNeil MM et al. Vaccine (2014).

CDC vaccine safety monitoring

CISA



**Clinical
Immunization
Safety
Assessment**

7 participating
healthcare organizations

vaccine safety experts

- assist U.S. healthcare providers with complex vaccine safety questions about their patients
- conduct clinical research



Influenza vaccine safety studies: mom, baby and pregnancy

Maternal influenza studies – general safety

- IIV and live attenuated influenza vaccines during pregnancy in VAERS, 1990-2009¹
 - No unusual patterns of pregnancy complications or fetal outcomes
- Influenza A (H1N1) 2009 monovalent vaccine during pregnancy in VAERS²
 - No concerning patterns of maternal or fetal outcomes
- IIV during pregnancy in VAERS, 2010-2016³
 - No vaccine safety concerns among pregnant women or their infants

1. Moro PL, et al. Am J Obstet Gynecol (2011).
2. Moro PL, et al. Am J Obstet Gynecol (2011).
3. Moro PL, et al. Drug Saf (2017).

Maternal influenza studies – maternal outcomes

- Medically attended maternal acute events in the VSD^{1,2}
 - Outcomes included allergic reactions, local reactions, neurologic events
 - No increased risk following IIV or monovalent H1N1 vaccines
- Feasibility of text message influenza vaccine safety monitoring during pregnancy^{3,4}
 - Prospective CISA study
 - Post-vaccination fever was infrequent and a typical pattern of maternal and neonatal health outcomes was observed

1. Nordin JD et al. Vaccine (2014)

2. Nordin JD et al. Obstet Gynecol (2013)

3. Stockwell M et al. AJPM (2017)

4. Registered at ClinicalTrials.gov www.clinicaltrials.gov (NCT01974050)

Maternal influenza studies – pregnancy outcomes

- Spontaneous abortion (SAB) in the VSD^{1,2}
 - No increased risk of SAB in the 28 days following IIV exposure during 2005-2007 influenza seasons¹
 - Increased risk of SAB in the 28 days following IIV exposure during 2010-2012 influenza seasons²
 - Risk seen in women vaccinated in prior influenza season
 - Follow up study evaluating subsequent influenza seasons in progress

1. Irving S et al. *Obstet Gynecol* (2013).

2. Donahue JG et al. *Vaccine* (2017).

Maternal influenza studies – pregnancy outcomes

- Medically attended adverse obstetric events in the VSD^{1,2}
 - Outcomes included hyperemesis, gestational hypertension, gestational diabetes, proteinuria, urinary tract infection
 - No increased risk following IIV or monovalent H1N1 vaccines
- Adverse birth outcomes in the VSD³
 - No increased risk of preterm birth or small for gestational age following IIV

1. Kharbanda EO et al. *Obstet Gynecol* (2013)

2. Nordin JD et al. *Vaccine* (2014)

3. Nordin JD et al. *J Pediatr* (2014)

Maternal influenza studies – infant outcomes

- Major birth defects after vaccination in VAERS, 1990 to 2014¹
 - Major birth defects were infrequently reported, with no condition reported disproportionately
- Major structural birth defects in the VSD²
 - No increased risk after first trimester IIV exposure
- Infant mortality and hospitalizations in the VSD³
 - No increased risk of infant death, hospitalization or hospitalizations from respiratory causes following maternal IIV exposure

1. Moro PL, et al. Birth Defects Res (2017).

2. Kharbanda EO et al. Journal of Pediatrics (2017).

3. Sukumaran L et al. Pediatrics [in press]

Systematic reviews and meta-analyses

- Outcomes: fetal death, spontaneous abortion, congenital malformations¹
 - In 19 studies, no increased risk of fetal death, spontaneous abortion, or congenital malformation following influenza vaccine
- Outcomes: stillbirth and spontaneous abortion²
 - In 7 studies, lower risk of stillbirth and no increased risk of spontaneous abortion following influenza vaccine
- Outcome: congenital malformations³
 - In 15 studies, no association was found between congenital defects and influenza vaccination at any trimester or at first trimester

1. McMillan M, et al. *Vaccine* (2015).
2. Bratting KN, et al. *Clinical Infectious Diseases* (2015).
3. Polyzos KA, et al. *Obstetrics and Gynecology* (2015).

A word about thimerosal

- Currently only used in multi-dose vials of influenza vaccine
- Institute of Medicine: “Immunization safety review: vaccines and autism”¹
 - Scientific evidence does not support a causal association between thimerosal-containing vaccines and autism
- CDC study: “Prenatal and infant exposure to thimerosal from vaccines and immunoglobulins and risk of autism”²
 - Case-control study in VSD found prenatal exposure to thimerosal containing immunizations did not increase the risk of autism

1. Institute of Medicine (US) Immunization Safety Review Committee. (2004).

2. Price CS, et al. Pediatrics (2010).

Tdap vaccine safety studies: mom, baby and pregnancy

Maternal Tdap studies – general safety

- Adverse events after Tdap vaccines in pregnant women in VAERS, 2005-2010¹
 - During a time when Tdap was not routinely recommended in pregnancy, no concerning patterns in maternal, infant, or fetal outcomes
- Enhanced surveillance of Tdap vaccines in pregnancy in VAERS, 2011-2015²
 - No new or unexpected adverse events were noted among vaccinated pregnant women after routine recommendations for maternal Tdap vaccination
 - Changes in reporting patterns expected, given the broader use of Tdap in pregnant women in the third trimester

1. Zheteyeva Y, et al. *Am J Obstet Gynecol* (2010).

2. Moro PL, et al. *Vaccine* (2016).

Maternal Tdap studies – maternal outcomes

- Medically attended maternal acute adverse events in the VSD¹⁻³
 - Outcomes included local reactions, allergic reactions, neurologic events
 - No increased risk following Tdap vaccine, concomitant Tdap and IIV, or following repeated doses of tetanus-containing vaccines
- Clinical study of Tdap safety in pregnant women in CISA (in progress)^{4,5}
 - Prospective observational study in pregnant and non-pregnant women
 - Preliminary findings: Tdap was well tolerated and immunogenic; proportion of reactions in pregnant women receiving repeat Tdap not higher than those receiving first Tdap

1. Kharbanda EO et al. *Vaccine* (2016)
2. Sukumaran L et al. *Obstet Gynecol* (2015)
3. Sukumaran L et al. *JAMA* (2015)
4. Presented to ACIP June 2016
5. Registered at ClinicalTrials.gov www.clinicaltrials.gov NCT02209623

Maternal Tdap studies – pregnancy outcomes

- Adverse obstetric events in the VSD¹
 - Small statistically significant increased risk of chorioamnionitis
 - Follow-up study evaluating infant morbidity showed no signals (next slide)
 - No increased risk of hypertensive disorders of pregnancy
- Chorioamnionitis reports to VAERS²
 - Chorioamnionitis was infrequently reported (<1% of pregnancy reports) over a period of 24 years²
- Adverse birth outcomes in the VSD^{1,3,4}
 - No increased risk of preterm delivery, small for gestational age following Tdap vaccine, concomitant Tdap and IIV, or following repeated doses of tetanus-containing vaccines

1. Kharbanda EO et al. JAMA (2014)
2. Datwani H, et al. Vaccine (2015).
3. Sukumaran L et al. Obstet Gynecol (2015)
4. Sukumaran L et al. JAMA (2015)

Maternal Tdap studies – infant outcomes

- Birth defects in the VSD¹
 - No increased risk of microcephaly or other structural birth defects
 - Response to concerns of increase in microcephaly in Brazil related to Zika
- Infant morbidity in the VSD²
 - No increased risk of tachypnea of newborn, neonatal sepsis, neonatal pneumonia, respiratory distress syndrome, newborn convulsions after maternal Tdap vaccine despite slight increase in diagnosed chorioamnionitis
- Infant mortality and hospitalizations in the VSD³
 - No increased risk for infant death, hospitalizations or respiratory hospitalizations after maternal Tdap

1. DeSilva M et al. JAMA (2016)
2. DeSilva M et al. Vaccine (2017)
3. Sukumaran L et al. Pediatrics [in press].

Maternal vaccine safety recap

Recap

- Pregnant women and neonates at increased risk of complications from influenza and pertussis disease
 - Vaccination during pregnancy important tool to protect pregnant women and their infants
- Pregnant women often excluded from drug and vaccine pre-licensure trials
 - Post-licensure monitoring crucial
- The CDC has a comprehensive mechanism for monitoring vaccine safety
 - Studies support the use of influenza and Tdap vaccines in pregnancy and are consistent with larger body of evidence

Your recommendation matters

- Consistently shown in literature to be the most influential factor in a patient's decision to receive an immunization





Maternal Immunization: Understanding Safety and Efficacy and Making a Strong Recommendation

Maternal Vaccination Communication Strategies

Ashley Brooks, MPH

Health Communication Specialist

National Center for Immunization and Respiratory Diseases

Overview

- ACIP-recommended immunization schedule for pregnant women
- Research surrounding maternal immunization communication
- Role of health care provider
- Use of CDC, ACOG, and ACNM messaging and resources to address patient questions

ACIP recommendations for pregnant women

Maternal Vaccination

Vaccine	Before pregnancy	During pregnancy	After pregnancy	Type of vaccine
Influenza	Yes	Yes, during flu season	Yes	Inactivated
Tdap	May be recommended; it is better to vaccinate during pregnancy when possible	Yes, during each pregnancy	Yes, immediately postpartum, if Tdap never received in lifetime; it is better to vaccinate during pregnancy	Toxoid/ Inactivated
Td	May be recommended	May be recommended, but Tdap is preferred	May be recommended	Toxoid
Hepatitis A	May be recommended	May be recommended	May be recommended	Inactivated
Hepatitis B	May be recommended	May be recommended	May be recommended	Inactivated
Meningococcal	May be recommended	Base decision on risk vs. benefit; inadequate data for specific recommendation	May be recommended	Inactivated
Pneumococcal	May be recommended	Base decision on risk vs. benefit; inadequate data for specific recommendation	May be recommended	Inactivated
HPV	May be recommended (through 26 years of age)	No	May be recommended (through 26 years of age)	Inactivated
MMR	May be recommended; once received, avoid conception for 4 weeks	No	May be recommended	Live
Varicella	May be recommended; once received, avoid conception for 4 weeks	No	May be recommended	Live

Influenza and pregnant women

Health and Economic Cost of Influenza

- Millions of cases per year, varies year to year
- 226,000 hospitalizations per year, >75% among adults¹
- 3,000–49,000 deaths per year, >90% among adults²
- Direct medical cost – \$10.4 billion³
- With loss of work and life – \$87 billion
- Estimates for 2015–2106⁴
 - 25 million illnesses
 - 11 million medical visits
 - 310,000 hospitalizations
 - 12,000 deaths



1. Thompson WW, et al. Influenza-Associated Hospitalizations in the United States. JAMA 2004;292:1333–1340

2. CDC. Estimates of deaths associated with seasonal influenza – United States, 1976–2007. MMWR 2010;59(33):1057–1062


3. Molinari, et al. The annual impact of seasonal influenza in the US: Measuring disease burden and costs. Vaccine 2007;25:5086–5096

4. CDC. Estimated Influenza Illnesses, Medical Visits, Hospitalizations, and Deaths Averted by Vaccination in the United States, 2017. Available at: www.cdc.gov/flu/about/disease/2015-16.htm

Influenza and Pregnancy


- Influenza illness during pregnancy
 - Higher risk for severe illness and complications
 - Increase in delivery complications (fetal distress, preterm labor, cesarean delivery)
- Vaccinating pregnant women
 - Protective levels of anti-flu antibody for mom, passive transfer of antibody for baby
 - Reduced risk for influenza infection and hospitalizations among infants <6 mos age
 - 36%↓ in respiratory illness for mom, 29%↓ for infants <6 mos age
 - 63%↓ in lab-confirmed flu among infants <6 mos age
- Influenza vaccination recommended for women who are or will be pregnant
 - CDC, American College of Obstetricians and Gynecologists, American College of Nurse Midwives, American Academy of Family Physicians

Influenza Vaccination Coverage Among Pregnant Women, 2010–2011 through 2016–2017 Influenza Seasons



Maternal Flu Vaccine Recommendation

- CDC recommends that pregnant women get a flu shot during any trimester of their pregnancy to protect themselves and their newborn babies from flu.
- By the end of October, if possible, to help ensure protection before flu activity begins to increase



Pertussis and pregnant women

Burden of Pertussis

- Notifiable disease based on clinical, lab, epi criteria
- 21,000 cases in 2015, 22% among adults (underdiagnosed and underreported)
- Transmission from adults to children
 - Disease most severe for infants
 - Among hospitalized, apnea (61%), pneumonia (23%), death (1%)



Pertussis Vaccination Recommendations

- Adults
 - 1 dose Tdap if previously not received, except for pregnant women
- Pregnant women
 - Direct protection for mom, indirect protection for baby
 - Infants of vaccinated moms were born with significantly higher anti-pertussis antibodies if Tdap given in pregnancy weeks 27–36
 - Concentration of anti-pertussis antibodies in infant cord blood higher when mothers vaccinated earlier in this window
 - Longer exposure to vaccine allows higher vaccine-induced antibody levels produced by mother and transferred to infant
 - Vaccination is recommended for *every* pregnancy
 - Cocooning alone may not be effective and it is difficult to implement

Pertussis Vaccination Recommendations

■ Adults

- 1 dose Tdap if previously not received, except for pregnant women

■ Pregnant women

- Direct protection for mom, indirect protection for infant
- Infants of vaccinated moms were hospitalized less often for pertussis antibodies if Tdap given in pregnancy
- Concentration of pertussis antibodies in infant cord blood higher when mothers vaccinated during pregnancy
- Longer exposure to vaccine allows higher vaccine-induced antibody levels produced by mother and transferred to infant

Administer 1 dose of Tdap every pregnancy preferably during early part of gestational weeks 27–36



Bottom Lines

- Pregnant women should get influenza vaccine and Tdap (for every pregnancy)
- But vaccination coverage rates remain low
- We know that health care provider recommendations have big impact
- So, focus on effective messaging and communication strategies

What does communication research tell us?

CDC Maternal Research



Summary of Findings from 2014 Mixed Methods Research

Methodology:

- Surveys
- Focus groups
- In depth interviews

Pregnant Women

- Low disease and vaccine awareness
- Protection for their babies is very important
- Want to be assured of safety
- High information-seeking
- Want information from ob-gyn or midwife

Ob-gyns

- Are recommending vaccines to pregnant patients
- Understand importance of maternal vaccination
- Low perceived susceptibility
- Systems barriers to stocking vaccines

Additional Research: November – December 2016

- Online survey and message testing with pregnant women
 - 251 pregnant women aged 18-45 years in U.S. receiving prenatal care
 - Mixed household income, age, and experience with pregnancy
 - Range of intention for flu and Tdap vaccines
- In-depth interviews with HCPs
 - 16 OB-GYNs and 8 certified nurse midwives (CNM)
 - Across all regions of U.S.
 - Included those that provide Tdap onsite + those that refer

Key Findings: Pregnant Women

■ Vaccine Recommendations

- 69% received flu vaccine recommendation and 41% received Tdap vaccine recommendation
- About 60% who received recommendations (for flu or Tdap vaccine) were told the vaccine was “extremely or very important”

■ Vaccine Acceptance

- More respondents had gotten or intended to get flu vaccine (59%) than Tdap (42%)
- 28% had decided not to get each of the vaccines

■ Vaccine Decision-making

- Pregnant women get vaccines because their prenatal care providers recommend them or because they heard the illnesses could harm their baby.
- They want information about safety of individual vaccines, side effects, and vaccine ingredients.

How HCPs Talk about Maternal Vaccines

- Most use similar Tdap and flu vaccine messages with patients
- Most discuss Tdap and flu vaccination concurrently, during initial intake visit
 - Use printed materials to help educate patients about vaccines
- Key message themes to facilitate vaccine conversations:
 - Disease susceptibility and severity
 - Vaccination benefits (protection, passive immunity)
 - Vaccine safety
- CNMs were more likely than OB-GYNs to feel uncomfortable making a strong recommendation for either vaccine, as they view it as a patient decision


Best Ways to Reach Pregnant Women

- Pregnant women get maternal vaccination formation from 3 main sources:
 - 80% HCPs (most important source for 60%)
 - 50% Internet health resources
 - 33% Family
- However, most are not actively looking for information about pregnancy vaccines
- Some pregnant women would be prompted by messages they see online to ask their HCP about maternal vaccination



Role of Health Care Provider

We know pregnant women have questions once they realize they need vaccines...



Are these diseases really dangerous?

Is it safe for me and my baby?

Can't I just get it after my baby is born (like my last pregnancy)?

Why every pregnancy?

Why hasn't my doctor talked to me about this?

Is it enough to just make sure everyone around my baby is vaccinated (or if we stay away from sick people)?

They may look to many sources for pregnancy-related information



Standards for Adult Immunization Practice

- All health care providers, including those who do not provide vaccine services, have role in ensuring adult patients up-to-date on vaccines
- Call to action for adult health care providers to
 - **ASSESS** vaccination status of all patients at every clinical encounter
 - Strongly **RECOMMEND** vaccines that patients need
 - **ADMINISTER** needed vaccines or **REFER** to a vaccine service provider
 - **DOCUMENT** vaccines received by patients in state vaccine registries


Present Vaccination as a Standard Part of Obstetric Care

- Provide your patients with information and resources about maternal vaccines during her first prenatal visit, and be sure to mention the timeframe for each vaccine when discussing her pregnancy
- Ensure your staff deliver consistent messaging about the importance of maternal vaccines
- Normalize vaccination as part of your patients' pregnancy care

Making a strong recommendation

Vaccination Uptake by Provider Recommendation and Offer

Influenza vaccination coverage before and during pregnancy among women pregnant any time during October 1, 2016 – January 31, 2017 and who visited a health care provider at least once since July 2016, by provider



1. CDC. Pregnant Women and Flu Vaccination, Internet Panel Survey

2. Ahluwalia IB et al. Obstet Gynecol 2010;116:949–55

3. Shavell VI et al. J Am Board Fam Med 2006;19:345–9

A Strong Recommendation Makes a Difference

- Providers should talk to pregnant patients about the importance of **on-time** vaccination
 - Pregnant patients need to be vaccinated to protect them and their babies
 - Pregnant patients may not be aware of the recommendations
 - Healthcare providers are patients most trusted sources of health information during their pregnancies.



Strong Vaccine Recommendation

- CDC's research indicates that some pregnant women do not feel their healthcare providers strongly recommend vaccines
- Providers should state clearly that they would like her to get vaccinated

“Today, I strongly recommend two vaccines to help protect you and your baby against the flu and whooping cough.”

HCPs can SHARE information with patients

- **SHARE** tailored reasons why the recommended vaccine is right for the patient
- **HIGHLIGHT** positive experiences with vaccines to reinforce the benefits and strengthen confidence in vaccination
- **ADDRESS** patient questions and any concerns about the vaccines
- **REMIND** patients about the protection vaccines can help provide from serious diseases
- **EXPLAIN** the potential costs of getting the disease

Resources and Tools



Digital Resources

- Website
- Quiz
- Motion graphic
- Listicle
- Digital Toolkit



#1. You aren't just protecting yourself –vaccines during pregnancy give your baby some early protection too!

You know that vaccines are meant to protect the person getting the shot against a disease, but during pregnancy, you and your baby are sharing everything, and that even includes disease protection. When you get some vaccines while you are pregnant, your body will create protective antibodies (proteins produced by the body to fight off diseases) and pass on some of those antibodies to your baby. These antibodies will give your baby some short-term protection against whooping cough and the flu (the 2 vaccines recommended during pregnancy) early in life.



Print Resources

Making a strong vaccine referral to pregnant women

Strategies for healthcare professionals



Making the Referral

High-quality evidence shows that healthcare professionals who make a vaccine referral to pregnant women are more likely to get the pregnant woman vaccinated. This system review of scientific evidence shows that healthcare professionals who make a vaccine referral to pregnant women are more likely to get the pregnant woman vaccinated.

Maternal Vaccination

Resources for healthcare professionals

Vaccines help keep your pregnant patients and their growing families healthy.

Last updated August 2015

Vaccine	Before pregnancy	During pregnancy	After pregnancy	Type of vaccine
MM2	Yes	Yes, through 36 weeks	Yes	Inactivated
Tdap	May be recommended. See Individual state immunization program for more details.	Yes, during early pregnancy	Yes, immediately following if they were not vaccinated during the pregnancy	Inactivated
Hib	May be recommended	May be recommended, but not preferred	May be recommended	Inactivated
Polio	May be recommended	May be recommended	May be recommended	Inactivated
Flu	May be recommended	May be recommended	May be recommended	Inactivated
MM4	May be recommended	May be recommended	May be recommended	Inactivated
MM5	May be recommended	May be recommended	May be recommended	Inactivated
MM6	May be recommended	May be recommended	May be recommended	Inactivated
MM7	May be recommended	May be recommended	May be recommended	Inactivated
MM8	May be recommended	May be recommended	May be recommended	Inactivated
MM9	May be recommended	May be recommended	May be recommended	Inactivated
MM10	May be recommended	May be recommended	May be recommended	Inactivated
MM11	May be recommended	May be recommended	May be recommended	Inactivated
MM12	May be recommended	May be recommended	May be recommended	Inactivated
MM13	May be recommended	May be recommended	May be recommended	Inactivated
MM14	May be recommended	May be recommended	May be recommended	Inactivated
MM15	May be recommended	May be recommended	May be recommended	Inactivated
MM16	May be recommended	May be recommended	May be recommended	Inactivated
MM17	May be recommended	May be recommended	May be recommended	Inactivated
MM18	May be recommended	May be recommended	May be recommended	Inactivated
MM19	May be recommended	May be recommended	May be recommended	Inactivated
MM20	May be recommended	May be recommended	May be recommended	Inactivated
MM21	May be recommended	May be recommended	May be recommended	Inactivated
MM22	May be recommended	May be recommended	May be recommended	Inactivated
MM23	May be recommended	May be recommended	May be recommended	Inactivated
MM24	May be recommended	May be recommended	May be recommended	Inactivated
MM25	May be recommended	May be recommended	May be recommended	Inactivated
MM26	May be recommended	May be recommended	May be recommended	Inactivated
MM27	May be recommended	May be recommended	May be recommended	Inactivated
MM28	May be recommended	May be recommended	May be recommended	Inactivated
MM29	May be recommended	May be recommended	May be recommended	Inactivated
MM30	May be recommended	May be recommended	May be recommended	Inactivated
MM31	May be recommended	May be recommended	May be recommended	Inactivated
MM32	May be recommended	May be recommended	May be recommended	Inactivated
MM33	May be recommended	May be recommended	May be recommended	Inactivated
MM34	May be recommended	May be recommended	May be recommended	Inactivated
MM35	May be recommended	May be recommended	May be recommended	Inactivated
MM36	May be recommended	May be recommended	May be recommended	Inactivated
MM37	May be recommended	May be recommended	May be recommended	Inactivated
MM38	May be recommended	May be recommended	May be recommended	Inactivated
MM39	May be recommended	May be recommended	May be recommended	Inactivated
MM40	May be recommended	May be recommended	May be recommended	Inactivated
MM41	May be recommended	May be recommended	May be recommended	Inactivated
MM42	May be recommended	May be recommended	May be recommended	Inactivated
MM43	May be recommended	May be recommended	May be recommended	Inactivated
MM44	May be recommended	May be recommended	May be recommended	Inactivated
MM45	May be recommended	May be recommended	May be recommended	Inactivated
MM46	May be recommended	May be recommended	May be recommended	Inactivated
MM47	May be recommended	May be recommended	May be recommended	Inactivated
MM48	May be recommended	May be recommended	May be recommended	Inactivated
MM49	May be recommended	May be recommended	May be recommended	Inactivated
MM50	May be recommended	May be recommended	May be recommended	Inactivated
MM51	May be recommended	May be recommended	May be recommended	Inactivated
MM52	May be recommended	May be recommended	May be recommended	Inactivated
MM53	May be recommended	May be recommended	May be recommended	Inactivated
MM54	May be recommended	May be recommended	May be recommended	Inactivated
MM55	May be recommended	May be recommended	May be recommended	Inactivated
MM56	May be recommended	May be recommended	May be recommended	Inactivated
MM57	May be recommended	May be recommended	May be recommended	Inactivated
MM58	May be recommended	May be recommended	May be recommended	Inactivated
MM59	May be recommended	May be recommended	May be recommended	Inactivated
MM60	May be recommended	May be recommended	May be recommended	Inactivated
MM61	May be recommended	May be recommended	May be recommended	Inactivated
MM62	May be recommended	May be recommended	May be recommended	Inactivated
MM63	May be recommended	May be recommended	May be recommended	Inactivated
MM64	May be recommended	May be recommended	May be recommended	Inactivated
MM65	May be recommended	May be recommended	May be recommended	Inactivated
MM66	May be recommended	May be recommended	May be recommended	Inactivated
MM67	May be recommended	May be recommended	May be recommended	Inactivated
MM68	May be recommended	May be recommended	May be recommended	Inactivated
MM69	May be recommended	May be recommended	May be recommended	Inactivated
MM70	May be recommended	May be recommended	May be recommended	Inactivated
MM71	May be recommended	May be recommended	May be recommended	Inactivated
MM72	May be recommended	May be recommended	May be recommended	Inactivated
MM73	May be recommended	May be recommended	May be recommended	Inactivated
MM74	May be recommended	May be recommended	May be recommended	Inactivated
MM75	May be recommended	May be recommended	May be recommended	Inactivated
MM76	May be recommended	May be recommended	May be recommended	Inactivated
MM77	May be recommended	May be recommended	May be recommended	Inactivated
MM78	May be recommended	May be recommended	May be recommended	Inactivated
MM79	May be recommended	May be recommended	May be recommended	Inactivated
MM80	May be recommended	May be recommended	May be recommended	Inactivated
MM81	May be recommended	May be recommended	May be recommended	Inactivated
MM82	May be recommended	May be recommended	May be recommended	Inactivated
MM83	May be recommended	May be recommended	May be recommended	Inactivated
MM84	May be recommended	May be recommended	May be recommended	Inactivated
MM85	May be recommended	May be recommended	May be recommended	Inactivated
MM86	May be recommended	May be recommended	May be recommended	Inactivated
MM87	May be recommended	May be recommended	May be recommended	Inactivated
MM88	May be recommended	May be recommended	May be recommended	Inactivated
MM89	May be recommended	May be recommended	May be recommended	Inactivated
MM90	May be recommended	May be recommended	May be recommended	Inactivated
MM91	May be recommended	May be recommended	May be recommended	Inactivated
MM92	May be recommended	May be recommended	May be recommended	Inactivated
MM93	May be recommended	May be recommended	May be recommended	Inactivated
MM94	May be recommended	May be recommended	May be recommended	Inactivated
MM95	May be recommended	May be recommended	May be recommended	Inactivated
MM96	May be recommended	May be recommended	May be recommended	Inactivated
MM97	May be recommended	May be recommended	May be recommended	Inactivated
MM98	May be recommended	May be recommended	May be recommended	Inactivated
MM99	May be recommended	May be recommended	May be recommended	Inactivated
MM100	May be recommended	May be recommended	May be recommended	Inactivated

For more information, visit www.cdc.gov/vaccines/pregnancy. Get an answer to your specific question by emailing cdc@cdc.gov or calling 800.CDC.INFO (232-6234).



Mamá, tú siempre protegerás a tu pequeño milagro.

Empieza ahora con tu vacuna contra la tosforina.

¿Le tocan las vacunaciones a tu bebé por venir al mundo? ¡Sí! Empezando desde ahora, puedes proteger a tu bebé y a tu familia con las vacunas.

¡Habla con tu médico, conéctate como la v...

What Vaccines to Expect When You're Expecting

Information for pregnant women

The CDC wants you to know that vaccines are an important part of a healthy pregnancy. Certain vaccines can be very helpful for you and your developing baby during your pregnancy. Getting vaccines during your pregnancy can help protect you both and provide your newborn with some early disease protection.

Pregnant women should get:

- The vaccine
- Whooping cough vaccine (also called Tdap)

For more information, visit www.cdc.gov/vaccines/pregnancy.

¿Puedes empezar a proteger a tu bebé de la tosforina desde antes del nacimiento?

Información para los expertos en salud

¿Sabías que la tosforina es una vacuna que puede ayudar a proteger a tu bebé antes de que nazca? ¡Sí! Empezando desde ahora, puedes proteger a tu bebé y a tu familia con las vacunas.

You can start protecting your baby from whooping cough before birth

Information for pregnant women

When you get the whooping cough vaccine during your pregnancy, your baby will be born with protection against whooping cough.

Whooping cough is a serious illness that can be very dangerous for babies. It can cause complications, including pneumonia, seizures, and even death. The good news is that you can protect your baby from whooping cough before birth by getting the whooping cough vaccine during your pregnancy.

Whooping cough is a serious illness that can be very dangerous for babies. It can cause complications, including pneumonia, seizures, and even death. The good news is that you can protect your baby from whooping cough before birth by getting the whooping cough vaccine during your pregnancy.

For more information, visit www.cdc.gov/vaccines/pregnancy.

ACOG Resources

For Providers | For Patients | Search Immunization Site | Submit

IMMUNIZATION for WOMEN
Immunization Information for Ob-Gyns and Their Patients

The American College of Obstetricians and Gynecologists

About Us | Diseases & Vaccines | Pregnancy | Vaccine Safety | Resources | Practice Management

ACOG Update on Zika Virus

Updated ACOG Tool Kit!
Influenza Immunization During Pregnancy 2015

ACOG's updated tool kit includes materials to help Ob-gyns and other health care providers communicate with pregnant women about the importance of receiving a flu shot.

[Click here for more information!](#)

Pregnancy | Content Spotlight | Immunization Schedules | Immunization News

Pregnant women are at higher risk of complications due to influenza. If your patient is pregnant she should receive the inactivated influenza vaccine, if she is breastfeeding she can receive the inactivated or live vaccine.

Download the ACOG app for iPhone and iPad and stay connected with authoritative information from the leading experts in women's health care. The Immunization applet is part of the ACOG app, it is a trusted and interactive resource on immunization best practices.

Talk to your patients about the importance of immunizations. Review the immunization schedule for any vaccinations they may need.

February 5, 2016 The U.S. Department of Health and Human Services released the first National Adult Immunization Plan which lays out four goals to increase adult immunization rates in the U.S. Read the National Adult Immunization Plan

February 4, 2016 The Surveillance of Vaccination Coverage Among Adult Populations — United States, 2014 noted an increase in vaccination coverage for Tdap and herpes zoster among adults. [Read the full MMWR.](#)

February 3, 2016 OOD HAN 387 Flu Season Begins, Severe Influenza Illness Reported. OOD urges rapid antiviral treatment of very ill and high risk suspect influenza patients without waiting for testing.

[All Immunization News](#)

- Immunization for Women website
- Patient & Provider Resources:
 - Clinical Guidance
 - FAQs
 - Recommendations
 - Safety
 - Coding and Reimbursement
 - Practice Management





Table 8. Current Procedural Terminology (CPT) Codes and ICD-9-CM Codes for Immunization (Code and Procedure)

Code	Code for Service	ICD-9-CM	Procedure
90.01	Immunization, influenza, inactivated	86.22	86.22
90.02	Immunization, influenza, live	86.22	86.22
90.03	Immunization, tetanus, toxoid	86.22	86.22
90.04	Immunization, tetanus, toxoid, adsorbed	86.22	86.22
90.05	Immunization, tetanus, toxoid, adsorbed, with diphtheria and pertussis antigens	86.22	86.22
90.06	Immunization, tetanus, toxoid, adsorbed, with diphtheria and pertussis antigens, and acellular pertussis antigens	86.22	86.22
90.07	Immunization, tetanus, toxoid, adsorbed, with diphtheria and pertussis antigens, and acellular pertussis antigens, and meningococcal polysaccharide antigen	86.22	86.22
90.08	Immunization, tetanus, toxoid, adsorbed, with diphtheria and pertussis antigens, and acellular pertussis antigens, and meningococcal polysaccharide antigen, and pneumococcal polysaccharide antigen	86.22	86.22
90.09	Immunization, tetanus, toxoid, adsorbed, with diphtheria and pertussis antigens, and acellular pertussis antigens, and meningococcal polysaccharide antigen, and pneumococcal polysaccharide antigen, and hepatitis B virus	86.22	86.22
90.10	Immunization, tetanus, toxoid, adsorbed, with diphtheria and pertussis antigens, and acellular pertussis antigens, and meningococcal polysaccharide antigen, and pneumococcal polysaccharide antigen, and hepatitis B virus, and hepatitis A virus	86.22	86.22
90.11	Immunization, tetanus, toxoid, adsorbed, with diphtheria and pertussis antigens, and acellular pertussis antigens, and meningococcal polysaccharide antigen, and pneumococcal polysaccharide antigen, and hepatitis B virus, and hepatitis A virus, and hepatitis C virus	86.22	86.22
90.12	Immunization, tetanus, toxoid, adsorbed, with diphtheria and pertussis antigens, and acellular pertussis antigens, and meningococcal polysaccharide antigen, and pneumococcal polysaccharide antigen, and hepatitis B virus, and hepatitis A virus, and hepatitis C virus, and hepatitis E virus	86.22	86.22
90.13	Immunization, tetanus, toxoid, adsorbed, with diphtheria and pertussis antigens, and acellular pertussis antigens, and meningococcal polysaccharide antigen, and pneumococcal polysaccharide antigen, and hepatitis B virus, and hepatitis A virus, and hepatitis C virus, and hepatitis E virus, and hepatitis G virus	86.22	86.22
90.14	Immunization, tetanus, toxoid, adsorbed, with diphtheria and pertussis antigens, and acellular pertussis antigens, and meningococcal polysaccharide antigen, and pneumococcal polysaccharide antigen, and hepatitis B virus, and hepatitis A virus, and hepatitis C virus, and hepatitis E virus, and hepatitis G virus, and hepatitis I virus	86.22	86.22
90.15	Immunization, tetanus, toxoid, adsorbed, with diphtheria and pertussis antigens, and acellular pertussis antigens, and meningococcal polysaccharide antigen, and pneumococcal polysaccharide antigen, and hepatitis B virus, and hepatitis A virus, and hepatitis C virus, and hepatitis E virus, and hepatitis G virus, and hepatitis I virus, and hepatitis J virus	86.22	86.22
90.16	Immunization, tetanus, toxoid, adsorbed, with diphtheria and pertussis antigens, and acellular pertussis antigens, and meningococcal polysaccharide antigen, and pneumococcal polysaccharide antigen, and hepatitis B virus, and hepatitis A virus, and hepatitis C virus, and hepatitis E virus, and hepatitis G virus, and hepatitis I virus, and hepatitis J virus, and hepatitis K virus	86.22	86.22
90.17	Immunization, tetanus, toxoid, adsorbed, with diphtheria and pertussis antigens, and acellular pertussis antigens, and meningococcal polysaccharide antigen, and pneumococcal polysaccharide antigen, and hepatitis B virus, and hepatitis A virus, and hepatitis C virus, and hepatitis E virus, and hepatitis G virus, and hepatitis I virus, and hepatitis J virus, and hepatitis K virus, and hepatitis L virus	86.22	86.22
90.18	Immunization, tetanus, toxoid, adsorbed, with diphtheria and pertussis antigens, and acellular pertussis antigens, and meningococcal polysaccharide antigen, and pneumococcal polysaccharide antigen, and hepatitis B virus, and hepatitis A virus, and hepatitis C virus, and hepatitis E virus, and hepatitis G virus, and hepatitis I virus, and hepatitis J virus, and hepatitis K virus, and hepatitis L virus, and hepatitis M virus	86.22	86.22
90.19	Immunization, tetanus, toxoid, adsorbed, with diphtheria and pertussis antigens, and acellular pertussis antigens, and meningococcal polysaccharide antigen, and pneumococcal polysaccharide antigen, and hepatitis B virus, and hepatitis A virus, and hepatitis C virus, and hepatitis E virus, and hepatitis G virus, and hepatitis I virus, and hepatitis J virus, and hepatitis K virus, and hepatitis L virus, and hepatitis M virus, and hepatitis N virus	86.22	86.22
90.20	Immunization, tetanus, toxoid, adsorbed, with diphtheria and pertussis antigens, and acellular pertussis antigens, and meningococcal polysaccharide antigen, and pneumococcal polysaccharide antigen, and hepatitis B virus, and hepatitis A virus, and hepatitis C virus, and hepatitis E virus, and hepatitis G virus, and hepatitis I virus, and hepatitis J virus, and hepatitis K virus, and hepatitis L virus, and hepatitis M virus, and hepatitis N virus, and hepatitis O virus	86.22	86.22

ACNM Resources

- Talking Points
- Position statements
- FAQ
- Posters, coloring books
- Curriculum
- Other resources
- <http://midwife.org/Immunization-Resources-for-Providers>
- SuperMom
- <http://ourmomentoftruth.com/your-health/importance-of-vaccines/>



What Can YOU Do?

- **GET VACCINATED**
- **TALK** to pregnant patients about maternal vaccines
 - Tell them why it's important for them and their babies
 - Make the conversation and recommendation memorable and compelling
- **ADMINISTER** indicated vaccines in your office if possible and **FOLLOW UP** to ensure receipt
- **USE** and **PROMOTE** resources available and encourage others to do the same
 - Include maternal vaccine resources in prenatal information packets
 - Promote resources and products through social media channels
- **EDUCATE** your staff about maternal vaccines
 - Identify or serve as a Vaccine Champion in your practice
- **ENCOURAGE** pregnant women to ask questions
- **TELL US** what else you need to help you communicate about vaccines

www.cdc.gov/vaccines/pregnancy

Contact Information

ACOG

Debra Hawks, MPH
dhawks@acog.org

Sarah Carroll, MPH
scarroll@acog.org

Sarah Wright, MPH
Swright@acog.org

Lindsey Regallis
lregallis@acog.org

ACNM

Elaine Germano, CNM, DrPH, FACNM
eagermano@acnm.org

Carol Hayes, CNM, MN, MPH
carolhayescnm@gmail.com

Questions?

For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348 www.cdc.gov



The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

Photographs and images included in this presentation are licensed solely for CDC/NCIRD online and presentation use. No rights are implied or extended for use in printing or any use by other CDC CIOs or any external audiences.



Extra Slides

Spontaneous abortion (SAB) and influenza vaccine

- Background rates of SAB range from 10-22%
- Miscarriages following (not attributed to) influenza vaccine are expected
- Limited data on first trimester influenza vaccine exposure
 - In a 2015 systematic review, 7 studies evaluating SAB found no risk
- Observational studies have limitations
 - Cannot prove flu vaccine was cause of miscarriage
- Original VSD study evaluating 2005-2007 seasons found no risk
 - Follow up study results expected 2019

How to talk to patients about SAB

- Health care decisions should be an ongoing discussion between provider and patient
- Providers should use clinical judgement, based on factors including the patient's health status, local influenza activity, and then benefits versus potential risks from flu vaccination when deciding whether and/or when to immunize their patient against influenza